IT201600109735A1 - Biomarkers and methods for in vitro diagnosis of multiple sclerosis. - Google Patents

Biomarkers and methods for in vitro diagnosis of multiple sclerosis.

Info

Publication number
IT201600109735A1
IT201600109735A1 IT102016000109735A IT201600109735A IT201600109735A1 IT 201600109735 A1 IT201600109735 A1 IT 201600109735A1 IT 102016000109735 A IT102016000109735 A IT 102016000109735A IT 201600109735 A IT201600109735 A IT 201600109735A IT 201600109735 A1 IT201600109735 A1 IT 201600109735A1
Authority
IT
Italy
Prior art keywords
biomarkers
methods
multiple sclerosis
vitro diagnosis
vitro
Prior art date
Application number
IT102016000109735A
Other languages
Italian (it)
Inventor
Giuseppe Lazzarino
Barbara Tavazzi
Giacomo Lazzarino
Angela Maria Amorini
Stasio Enrico Di
Claudio Gasperini
Original Assignee
Giuseppe Lazzarino
Barbara Tavazzi
Giacomo Lazzarino
Angela Maria Amorini
Stasio Enrico Di
Claudio Gasperini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuseppe Lazzarino, Barbara Tavazzi, Giacomo Lazzarino, Angela Maria Amorini, Stasio Enrico Di, Claudio Gasperini filed Critical Giuseppe Lazzarino
Priority to IT102016000109735A priority Critical patent/IT201600109735A1/en
Priority to PCT/IT2017/000238 priority patent/WO2018078665A1/en
Publication of IT201600109735A1 publication Critical patent/IT201600109735A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
IT102016000109735A 2016-10-31 2016-10-31 Biomarkers and methods for in vitro diagnosis of multiple sclerosis. IT201600109735A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102016000109735A IT201600109735A1 (en) 2016-10-31 2016-10-31 Biomarkers and methods for in vitro diagnosis of multiple sclerosis.
PCT/IT2017/000238 WO2018078665A1 (en) 2016-10-31 2017-10-31 Biomarkers and methods for in vitro diagnosis of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000109735A IT201600109735A1 (en) 2016-10-31 2016-10-31 Biomarkers and methods for in vitro diagnosis of multiple sclerosis.

Publications (1)

Publication Number Publication Date
IT201600109735A1 true IT201600109735A1 (en) 2018-05-01

Family

ID=58163040

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000109735A IT201600109735A1 (en) 2016-10-31 2016-10-31 Biomarkers and methods for in vitro diagnosis of multiple sclerosis.

Country Status (2)

Country Link
IT (1) IT201600109735A1 (en)
WO (1) WO2018078665A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7333942B2 (en) * 2019-06-07 2023-08-28 株式会社スタージェン Method for predicting effect of ATP-enhancing therapy on neurodegenerative disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMORINI A M ET AL: "Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 42, no. 10-11, 1 July 2009 (2009-07-01), pages 1001 - 1006, XP026173708, ISSN: 0009-9120, [retrieved on 20090331], DOI: 10.1016/J.CLINBIOCHEM.2009.03.020 *
AMORINI ANGELA M ET AL: "Serum lactate as a novel potential biomarker in multiple sclerosis", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, vol. 1842, no. 7, 2014, pages 1137 - 1143, XP028650680, ISSN: 0925-4439, DOI: 10.1016/J.BBADIS.2014.04.005 *
BARBARA TAVAZZI ET AL: "Serum Metabolic Profile in Multiple Sclerosis Patients", MULTIPLE SCLEROSIS INTERNATIONAL, vol. 2011, 1 January 2011 (2011-01-01), pages 1 - 8, XP055372543, ISSN: 2090-2654, DOI: 10.1155/2011/167156 *
GIACOMO LAZZARINO ET AL: "Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis", MOLECULAR NEUROBIOLOGY, 8 November 2016 (2016-11-08), US, XP055372547, ISSN: 0893-7648, DOI: 10.1007/s12035-016-0257-9 *

Also Published As

Publication number Publication date
WO2018078665A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
EP3543880C0 (en) Stroke diagnosis and prognosis system
IL260678B (en) Systems and methods for improving disease diagnosis
KR20180084817A (en) Anti-SIGLEC-9 antibodies and methods of using the same
EP3265588A4 (en) Methods for assessing the risk of disease occurrence or recurrence using expression level and sequence variant information
DK3656875T3 (en) Non-invasive prenatal diagnosis
CR20180013A (en) ANTI-TAU ANTIBODIES AND METHODS OF USE.
CR20170095A (en) ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS
CR20190271A (en) Anti-tau antibodies and methods of use
CR20160362A (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
EP3232198A4 (en) Biomarker for diagnosis of hepatoma and use thereof
CL2016003291A1 (en) Interferon alpha and omega antagonist antibody
EP3376229A4 (en) Biomarker for diagnosing depression and use of said biomarker
ITUA20164448A1 (en) Metagenomic method for in vitro diagnosis of intestinal dysbiosis.
AR107786A1 (en) METHODS AND COMPOSITIONS FOR DETECTION AND DIAGNOSIS OF RENAL DISEASE AND PERIODONTAL DISEASE
BR112016024803A2 (en) abrasive supports and methods of their formation
BR112017005252A2 (en) method for detection of target molecule and kit for use in said method.
ITUB20153333A1 (en) METHOD FOR THE REALIZATION OF AN ELASTIC LAMINATE AND ELASTIC LAMINATE PRODUCT
ITUB20152405A1 (en) PROCEDURE FOR THE CONSTRUCTION OF ALUMINUM OBJECTS, ALUMINUM ALLOYS, LIGHT ALLOYS, BRASS, BRONZE AND THE LIKE.
DE112017006468A5 (en) AL-CAST ALLOY
IT201700025981A1 (en) Barrel and method for its manufacture
DK3445884T3 (en) Ferritic alloy
DE112015003841A5 (en) DI AND TRIPHOSPHATE PROPHARMAKA
DE112017004089A5 (en) Al-cast alloy
DK3432887T3 (en) Anti-tuberculosis drug
IT201600109735A1 (en) Biomarkers and methods for in vitro diagnosis of multiple sclerosis.